PEG — Pharma Equity A/S Income Statement
0.000.00%
- DKK306.88m
- DKK324.29m
Annual income statement for Pharma Equity A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 14.4 | 32.6 | -4.91 | -3.03 | 20.9 |
Operating Profit | -14.4 | -32.6 | 4.91 | 3.03 | -20.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.4 | -32.9 | 5.39 | 3.48 | -26.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.4 | -32.9 | 5.39 | 3.48 | -24.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.4 | -32.9 | 5.39 | 3.48 | -24.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.4 | -32.9 | 5.39 | 3.48 | -24.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.285 | -0.73 | 0.015 | -0.052 | -0.023 |
Dividends per Share |